On February 19, 2009, the US Food and Drug Administration (FDA) approved the licensing of febuxostat for the treatment of hyperuricemia in patients with chronic gout. This is the only approved indication for the drug at this time. Febuxostat will be marketed under the trade name Uloric and is manufactured by Takeda Pharmaceuticals. Links to summaries of clinical trials of febuxostat previously posted on this website are accessed at the following links:
- Interim Results from the Febuxostat Comparative Extension Long-Term Study
- Comparison of Febuxostat and Allopurinol on Serum Urate Levels
